Sequence information
DRAVP ID DRAVPc061
Name Sotrovimab
Sequence Not available
Molecular Formula Not Available
Condition/Disease COVID-19
Group Approved
Type Antibody
Description Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus.Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.
Active sequence/Structure
External Links
DrugBank Accession Number DB16355
Pubchem ID 472422617
CHEMBL ID CHEMBL4650524
UNII 1MTK0BPN8V
CAS 2423014-07-5
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04790786 | UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19) | COVID-19 | Completed | Phase 4 | Erin McCreary |
| NCT04779879 | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (COMET-PEAK) | COVID-19 | Completed | Phase 2 | Vir Biotechnology, Inc. |
